The Rate of CSF Formation, Resistance to Reabsorption of CSF, and Aperiodic Analysis of the EEG Following Administration of Flumazenil to Dogs

Alan A. Artru, M.D.*

The effects of flumazenil, a benzodiazepine antagonist, on the rate of cerebrospinal fluid (CSF) formation (\(V_f\)), resistance to reabsorption of CSF (\(R_s\)) and the electroencephalogram (EEG) was determined in 15 dogs anesthetized with halothane (0.4%, end-expired) and nitrous oxide (66%, inspired) in oxygen. In six dogs the responses to flumazenil were measured during administration of midazolam (1.6 mg/kg followed by 1.25 mg·kg\(^{-1}\)·h\(^{-1}\), intravenously) given along with inhalational anesthesia, whereas in the other nine dogs the responses to flumazenil were measured during inhalational anesthesia without midazolam. \(V_f\) and \(R_s\) were determined using ventriculocisternostomy perfusion, and EEG activity was evaluated using aperiodic analysis. Flumazenil, 0.0025 and 0.16 mg/kg, was administered both when CSF pressure was normal and when CSF pressure was increased to 36–38 cmH\(_2\)O by continuous infusion of mock CSF. Flumazenil produced no statistically significant change in \(V_f\). Flumazenil did produce inconsistent and relatively small changes in \(R_s\). Quantitative aperiodic analysis indicated changes in EEG activity only when the larger dose of flumazenil was given to dogs receiving midazolam. At normal CSF pressure the changes were consistent and were comprised of decreases in \(\delta\), \(\alpha\), and total hemispheric power. At elevated CSF pressure the changes were less consistent. It is concluded that smaller doses of flumazenil (which cause no EEG changes with the present method of analysis) and larger doses of flumazenil (which reverse midazolam-induced increase of \(\alpha\) and total hemispheric activity) produce no change of \(V_f\) and no consistent change of \(R_s\). Although flumazenil given in the presence of midazolam may increase \(R_s\), thereby increasing CSF pressure and impairing contraction of CSF volume, this effect is not likely to be clinically important. (Key words: Anesthetics, intravenous; midazolam. Antagonists, benzodiazepine: flumazenil. Brain: electroencephalogram; intracranial pressure. Cerebrospinal fluid: formation; pressure; reabsorption. Hypnotics: midazolam.)

FLUMAZENIL is an imidazodiazepine that binds to benzodiazepine receptor sites in the brain. Studies on the cerebral effects of flumazenil reported that doses of 0.0025–1.0 mg/kg increased cerebrospinal fluid (CSF) pressure in patients and dogs receiving midazolam.\(^1\)†‡

One cause for flumazenil-induced increase of CSF pressure appears to be cerebral vasodilation. Flumazenil doses of 0.01–1.0 mg/kg were reported to produce a significant decrease of cerebral vascular resistance and increase of cerebral blood flow (CBF). Other causes for flumazenil-induced increase of CSF pressure may be alteration of the rate of CSF formation (\(V_f\)), resistance to reabsorption of CSF (\(R_s\)), or intracranial volume-pressure relationships. One aim of the present study was to determine whether flumazenil produces significant changes in \(V_f\) and/or \(R_s\) in dogs receiving midazolam.

Flumazenil also was previously reported to cause activation of the electroencephalogram (EEG) when given to patients or dogs receiving midazolam.\(^1\)§ The method of EEG analysis was spectral analysis of the EEG based on fast Fourier transform, or visual inspection of "raw" EEG activity. However, the significance of flumazenil-induced changes in EEG activity is not certain because the method of EEG analysis used in the previous studies may not be optimal for statistical treatment. Fast Fourier transform collects data only in repeated windows of finite time, and it has been proposed by some authors that the technique is not ideally suited for the stochastic nature of the EEG signal.\(^2\) Visual inspection of "raw" EEG does not provide numerical data. A second aim of the present study was to examine the effects of flumazenil on the EEG using aperiodic analysis, a technique designed to continuously analyze waveforms not characterized by consistent periods.

A third aim of this study was to examine the effects of flumazenil on \(V_f\), \(R_s\), and EEG at elevated CSF pressure where CSF pressure was increased by volume expansion of the CSF space. The technique used for CSF volume expansion was continuous infusion of mock CSF.\(^3\) This technique and the level of increase of CSF pressure were designed to avoid focal cerebral ischemia and distortion of intracranial contents.\(^3\)

If in the present study flumazenil was found to alter \(V_f\), \(R_s\), or the EEG in dogs receiving midazolam, it would not be certain whether the changes resulted from reversal of benzodiazepine effect or a direct action of flumazenil. A fourth aim of the present study was to determine whether a preexisting benzodiazepine effect altered the

* Professor of Anesthesiology.

† Artru AA: Cerebral effects of flumazenil given with or without prior administration of midazolam and at normal or elevated CSF pressure (abstract). Anesthesiology Review 15:104–105, 1988

response of $\bar{V}_t$, $R_a$, or the EEG to flumazenil. For that purpose, two groups of dogs were studied—one receiving midazolam and one not receiving midazolam.

**Methods**

**Animal Preparation**

This study was approved by the Animal Care Committee of the University of Washington. Twelve unmedicated mongrel dogs (weighing 15–22 kg) were studied. Anesthesia was induced with halothane (>1.5% inspired concentration) and nitrous oxide (N$_2$O, 66%, inspired) in oxygen. The trachea was intubated, expired CO$_2$ was continuously monitored (Beckman Medical Gas Analyzer, Model LB2, Beckman Instruments, Inc., Fullerton, California), and ventilation was regulated by a servocore to maintain expired CO$_2$ at normocapnia. The right femoral artery was cannulated to permit arterial blood sampling for blood–gas analysis and to permit continuous monitoring of systemic arterial blood pressure and heart rate. Mean arterial blood pressure (MAP) was determined by electronic integration. A urinary catheter was inserted, the right femoral vein was cannulated for saline and drug administration, and temperature was monitored by a nasopharyngeal thermistor probe. Intravenous infusion of pancuronium 2–4 mg/h maintained muscle relaxation. Temperature was maintained at 37.0 ± 0.5°C by heat lamps. Depletion of vascular volume was minimized by continuous infusion of saline at 4–6 ml·kg$^{-1}$·h$^{-1}$.

The EEG was recorded using bilateral frontoparietal electrodes and a Lifescan™ Brain Activity Monitor System (Diatesk Medical™ Technology Incorporated, San Diego, California) with a bandpass of 0.5 to 29.9 Hz. Electrodes were adjusted to maintain impedance between electrode pairs at <7 kΩ. This system uses aperiodic analysis to convert the analog EEG signal into a set of digital parameters.24 With aperiodic analysis, local extremes in the unprocessed EEG waveforms are identified. The height of each peak and valley and the time of occurrence are measured. Amplitude is defined as the average of the difference in voltage between a peak and the preceding and following valleys. Frequency is defined as the inverse of the difference in the time of occurrence of the two valleys. Computer (Zenith Data Systems, Glenview, Illinois) analysis of the EEG was performed using a Lifescan™ Research System program. For each 60 s of EEG activity the following values were determined for both the right and left cerebral hemisphere: the power (calculated as amplitude squared) and number of waves in each of the standard frequency bins (δ, 0.5–3 Hz; θ, 3–8 Hz; α, 8–12 Hz; and β, 12–30 Hz), total hemispheric power, and the activity edge (the frequency below which 80% of hemispheric power was present).

A burr hole was placed over the left hemisphere and a catheter was directed into the underlying lateral ventricle. The posterior neck muscles were surgically separated to expose the atlantooccipital membrane, and a catheter was directed into the cisterna magna. A 0.5-ml sample of CSF was obtained from the cisternal cannula for measurement of osmolality using a Wescor Model 5100 B Vapor Pressure Osmometer (Wescor, Inc., Logan, Utah). Mock CSF of matching osmolality was prepared by mixing standard solutions (osmolality 290, 300, or 310 mOsm/kg) labeled with blue dextran (1 mg/ml) (Sigma Chemical Co., St. Louis, Missouri). Details of this animal preparation have been previously reported.6,7

Mock CSF was infused into the ventricle and the mixture of mock and native CSF was permitted to flow passively out of the cisterna magna through a short length of tubing attached to the cisternal cannula. Details for the technique of ventriculocisternal perfusion have been previously reported.8,9 The infusion rate ($\bar{V}_i$) was controlled with a roller pump and gradually increased to 0.6 ml/min, while ventricular CSF pressure was continuously monitored. The open end of the cisternal outflow tubing was placed at the same height as the CSF level present in the cisternal and ventricular cannula before perfusion was begun. This arrangement did not alter CSF pressure from the value normally occurring in the intact animal because the height of the open end of the outflow tubing determines CSF pressure during open ventriculocisternal perfusion. Successful ventriculocisternal perfusion was indicated by outflow of labeled CSF from the cisternal cannula with no increase in ventricular CSF pressure above pre-perfusion values. This initial period of open ventriculocisternal perfusion allowed for equilibrium of labeled mock CSF with native CSF in the intracranial and cisternal CSF spaces of the dog. Details of this modified open ventriculocisternal perfusion technique have been previously reported.6,10

After 1 h of ventriculocisternal perfusion, $\bar{V}_i$ was gradually reduced to 0.3 ml/min. The concentration of blue dextran in cisternal outflow samples was determined intermittently using light absorbance at 620 nm on a Beckman DU-2 Spectrophotometer (Beckman Instruments, Inc., Fullerton, California) (fitted with a Gilford absorbance indicator, Gilford Instrument Laboratories, Inc., Oberlin, Ohio). Equilibration of the tracer was considered complete when measured blue dextran concentrations in three consecutive samples of cisternal outflow (collection time = 4–6 min per sample) agreed within 2%. Total equilibrium time was 90 min.

Prior to the completion of the surgical preparation six dogs (group 1) received midazolam 1.6 mg/kg intravenously followed by continuous iv infusion of midazolam at 1.25 mg·kg$^{-1}$·h$^{-1}$. Intravenous infusion of midazolam continued until the end of the study. The other six dogs
(group 2) received no midazolam. In both groups wound edges were infiltrated with bupivacaine (0.5%) during the surgical preparations, and the expired concentration of halothane was decreased to 0.4% (end-expired concentration determined by gas chromatography, N₂O continued) after completion of the surgical preparation.

**Experimental Period**

The experimental period began once tracer equilibration was complete. \( V_f \) and \( R_a \) were determined at each of six experimental conditions: three during normal CSF pressure and the same three during increased CSF pressure. The three experimental conditions were as follows: 1) no flumazenil (control), 2) flumazenil 0.0025 mg/kg, and 3) flumazenil 0.16 mg/kg. These doses of flumazenil were selected because the smaller dose previously was reported to reverse the reduction of cerebral metabolic rate for oxygen and alteration of EEG activity caused by midazolam and the larger dose previously was reported to also decrease cerebral vascular resistance, increase cerebral blood flow, and increase CSF pressure compared with dogs not receiving midazolam.† Each dose of flumazenil was given intravenously over 60 s. Three dogs were examined first at normal CSF pressure and then at increased CSF pressure, and three dogs were examined first at elevated CSF pressure and then at normal CSF pressure in both group 1 (midazolam) and group 2 (no midazolam). Assignment to these two sequences was randomized. At each experimental condition \( V_f \) and the rate of reabsorption of CSF (\( V_a \)) were determined twice—once at the target CSF pressure (whether normal or increased) and once with the CSF pressure increased 10 cmH₂O above the target value. It was necessary to determine \( V_a \) twice at each experimental condition (i.e., at two CSF pressures) to permit calculation of \( R_a \). Normal CSF pressure was defined as that when the open end of the cisternal outflow tubing was placed at the same height as the CSF level present in the cisternal and ventricular canulae before perfusion was begun. Increased CSF pressure was defined as CSF pressure when the open end of the cisternal outflow tubing was placed approximately 30 cm above the level used for normal CSF pressure.

Sixty minutes was allowed for restabilization when CSF pressure was changed from normal to increased or from increased to normal. At least 27 min (the first 17 min with \( V_f = 0.6 \) ml/min followed by at least 10 min with \( V_f = 0.3 \) ml/min) was allowed between each of the six experimental conditions to permit reequilibration of the tracer. At each condition three consecutive samples of cisternal outflow were collected (collection time = 3–6 min per sample) for determinations of \( V_f \) and \( V_a \). The duration of the experimental period was 7 h.

\( V_f \) and \( V_a \) were calculated as previously described according to the formulas of Heisey et al. For these calculations concentrations of blue dextran in samples of the labeled mock CSF being perfused into the ventricle also were determined using light absorbance at 620 nm. For the normal CSF pressure conditions, \( R_a \) was calculated from the two \( V_a \) values determined at normal CSF pressure and 10 cmH₂O above normal CSF pressure. For the elevated CSF pressure conditions, \( R_a \) was calculated from the two \( V_a \) values determined at elevated CSF pressure and 10 cmH₂O above elevated CSF pressure. By definition, \( R_a \) is a reciprocal measure of the slope relating \( V_a \) (expressed as ml/min) to CSF pressure (expressed as cmH₂O). Systemic values also were recorded at each experimental condition. EEG data were recorded for 4 min prior to each dose of flumazenil and for 10 min following each dose of flumazenil.

**Statistical Analysis**

Statistical comparisons within groups were made using repeated-measures analysis of variance (ANOVA), and comparisons between groups were made using one-way and multiple ANOVA. Multiple ANOVA indicated that in both group 1 (midazolam) and group 2 (no midazolam), dogs studied first at increased and then at normal CSF pressure responded to both flumazenil and the increase of CSF pressure similarly to dogs studied first at normal and then at increased CSF pressure. Thus, the data from each group (n = 6) were treated as a set and were not subdivided according to the sequence of increase of CSF pressure. Comparisons between the present groups and previously reported "normal" values for \( V_f \) and \( R_a \) for dogs were made using one-way ANOVA. Where the calculated F value exceeded the critical value for the 0.05 probability level, the Student-Newman-Keuls' test was used to determine which differences were significant at \( P < 0.05 \). Values are tabulated as mean ± SD.

**Results**

Mean control \( V_f \) values ranged from 0.035 ± 0.009 to 0.040 ± 0.012 ml/min in dogs receiving midazolam, and from 0.028 ± 0.011 to 0.037 ± 0.011 ml/min in dogs not receiving midazolam (tables 1 and 2). Flumazenil produced no significant change of \( V_f \) in either group whether CSF pressure was normal or elevated. Within groups, control \( V_f \) values at normal CSF pressure were not different from those at increased CSF pressure. At either CSF pressure, control \( V_f \) values were not different between groups.

At normal CSF pressure, \( R_a \) in dogs receiving midazolam (218 ± 32 cmH₂O · ml⁻¹ · min⁻¹) was not different than \( R_a \) in dogs not receiving midazolam (268 ± 24 cmH₂O · ml⁻¹ · min⁻¹). The smaller dose of flumazenil increased \( R_a \) by 77% in dogs receiving midazolam, but...
Table 1. Cerebral Values and Mean Arterial Pressure in Dogs Receiving Midazolam (n = 6; mean ± SD)

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Flumazenil 0.0025 mg/kg</th>
<th>Flumazenil 0.16 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CSF State 1</td>
<td>CSF State 2</td>
<td>CSF State 1</td>
</tr>
<tr>
<td>Normal CSF pressure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$V_t$ (ml/min)</td>
<td>$0.035 ± 0.009$</td>
<td>$0.036 ± 0.009$</td>
<td>$0.035 ± 0.009$</td>
</tr>
<tr>
<td>$R_a$ (cmH₂O·min⁻¹)</td>
<td>$218 ± 32$</td>
<td>$365 ± 18$†</td>
<td>$251 ± 20$†</td>
</tr>
<tr>
<td>CSF pressure, intraventricular (cmH₂O)</td>
<td>$10 ± 2$</td>
<td>$10 ± 1$†</td>
<td>$12 ± 3$†</td>
</tr>
<tr>
<td>Mean arterial pressure (mmHg)</td>
<td>$102 ± 15$</td>
<td>$104 ± 7$</td>
<td>$108 ± 8$†</td>
</tr>
<tr>
<td>Increased CSF pressure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$V_t$ (ml/min)</td>
<td>$0.040 ± 0.012$</td>
<td>$0.040 ± 0.012$</td>
<td>$0.039 ± 0.010$</td>
</tr>
<tr>
<td>$R_a$ (cmH₂O·min⁻¹)</td>
<td>$104 ± 14$‡</td>
<td>$116 ± 11$†</td>
<td>$130 ± 10$‡</td>
</tr>
<tr>
<td>CSF pressure, intraventricular (cmH₂O)</td>
<td>$38 ± 2$‡</td>
<td>$38 ± 2$†</td>
<td>$38 ± 2$†</td>
</tr>
<tr>
<td>Mean arterial pressure (mmHg)</td>
<td>$109 ± 7$</td>
<td>$111 ± 12$</td>
<td>$115 ± 10$</td>
</tr>
</tbody>
</table>

* Significantly different from values at the other experimental conditions for that CSF pressure, $P < 0.05$.
† Significantly different from value at target CSF pressure, $P < 0.05$.
‡ Significantly different from corresponding control value at normal CSF pressure, $P < 0.05$.

the larger dose produced no significant change in $R_a$. The larger dose of flumazenil decreased $R_a$ by 10% in dogs not receiving midazolam, whereas the smaller dose produced no significant change in $R_a$. In both groups increasing CSF pressure to 36–38 ± 2 cmH₂O decreased $R_a$ by 47–52%. At this CSF pressure the larger dose of flumazenil increased $R_a$ by 25% in the dogs receiving midazolam, but the smaller dose caused no significant change in $R_a$. Neither flumazenil dose changed $R_a$ in dogs not receiving midazolam at increased CSF pressure.

At both normal and increased CSF pressure, one-way ANOVA indicated that the combination of $\theta$ and $\alpha$ power and number of waves was greater in dogs receiving midazolam than in dogs not receiving midazolam. Within each of the two groups of dogs, elevation of CSF pressure caused no significant change in number of waves or power in any of the frequency bins, and no change in total hemispheric power or activity edge. In dogs receiving midazolam the larger dose of flumazenil decreased $\alpha$, $\theta$, and total hemispheric power at normal CSF pressure, both on the visual display of processed EEG activity (fig. 1) and by quantitative analysis of the EEG (fig. 2). These decreases attained statistical significance at 2–3 min postflumazenil and remained significant through 10 min postflumazenil. At increased CSF pressure the larger dose of

Table 2. Cerebral Values and Mean Arterial Pressure in Dogs Not Receiving Midazolam (n = 6; mean ± SD)

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Flumazenil 0.0025 mg/kg</th>
<th>Flumazenil 0.16 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CSF State 1</td>
<td>CSF State 2</td>
<td>CSF State 1</td>
</tr>
<tr>
<td>Normal CSF pressure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$V_t$ (ml/min)</td>
<td>$0.032 ± 0.011$</td>
<td>$0.028 ± 0.011$</td>
<td>$0.029 ± 0.009$</td>
</tr>
<tr>
<td>$R_a$ (cmH₂O·min⁻¹)</td>
<td>$268 ± 24$</td>
<td>$268 ± 24$</td>
<td>$233 ± 30$</td>
</tr>
<tr>
<td>CSF pressure, intraventricular (cmH₂O)</td>
<td>$11 ± 2$</td>
<td>$11 ± 2$†</td>
<td>$11 ± 2$†</td>
</tr>
<tr>
<td>Mean arterial pressure (mmHg)</td>
<td>$111 ± 13$</td>
<td>$107 ± 11$</td>
<td>$107 ± 11$</td>
</tr>
<tr>
<td>Increased CSF pressure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$V_t$ (ml/min)</td>
<td>$0.037 ± 0.011$</td>
<td>$0.037 ± 0.011$</td>
<td>$0.037 ± 0.008$</td>
</tr>
<tr>
<td>$R_a$ (cmH₂O·min⁻¹)</td>
<td>$143 ± 18$‡</td>
<td>$143 ± 18$‡</td>
<td>$101 ± 23$</td>
</tr>
<tr>
<td>CSF pressure, intraventricular (cmH₂O)</td>
<td>$36 ± 2$‡</td>
<td>$36 ± 2$†</td>
<td>$36 ± 2$†</td>
</tr>
<tr>
<td>Mean arterial pressure (mmHg)</td>
<td>$113 ± 9$</td>
<td>$110 ± 10$</td>
<td>$112 ± 8$</td>
</tr>
</tbody>
</table>

* Significantly different from values at the other experimental conditions for that CSF pressure, $P < 0.05$.
† Significantly different from value at target CSF pressure, $P < 0.05$.
‡ Significantly different from corresponding control value at normal CSF pressure, $P < 0.05$. 
flumazenil decreased $\alpha$ and total hemispheric power by quantitative analysis but not on the visual display. These decreases were less consistent than at normal CSF pressure and attained statistical significance only at 6, 9, and 10 min postflumazenil for $\alpha$ power and at 5–7, 9, and 10 min postflumazenil for total power.

Raising the distal end of the cisternal outflow tubing by 10 or 30 cm increased CSF pressure by 10 or 30 cmH$_2$O, respectively. Systemic values did not differ between any experimental conditions at normal or elevated CSF pressure within each group and were therefore combined (table 4). Combined systemic values did not differ between groups.

**Discussion**

The results of this study indicate that flumazenil does not alter $V_f$, whether it is given at normal or increased CSF pressure. Following administration of flumazenil 0.0025 or 0.16 mg/kg, $V_f$ was unchanged both in dogs receiving midazolam and in dogs not receiving midazolam. In contrast, flumazenil did produce some changes in $R_a$. These were inconsistent, with statistical increases occurring following two of the four flumazenil doses in dogs receiving midazolam and a decrease occurring following one of the four doses in dogs not receiving midazolam. It should be noted that with one of the two increases in $R_a$ (at increased CSF pressure in dogs receiving midazolam), the value was greater than the control value for that group but was not different from the control value (at normal CSF pressure) for the group not receiving midazolam.

With the decrease in $R_a$ (at normal CSF pressure in dogs not receiving midazolam), the value was less than the control value for that group but was not different from the control value (at normal CSF pressure) for the group receiving midazolam.

The results of this study also indicate that flumazenil produced changes in EEG activity in dogs receiving midazolam but not in dogs not receiving midazolam. The visual display of these EEG changes on the present aperiodic analysis program were similar to those previously reported by Fleischer et al.\textsuperscript{1} on the visual display of a power spectral analysis program. In the previous study flumazenil 1.0 mg/kg produced a dramatic decrease in amplitude and an increase in frequency to primarily $\beta$ activity, with EEG activity returning to a preflumazenil pattern over the next 15 min. In the present study the visual data were similar to those of the previous study. Quantitative analysis of the EEG indicated that flumazenil-induced EEG changes were comprised of decrease in power but not number of waves or activity edge in dogs receiving midazolam at normal CSF pressure. There were also significant EEG changes in dogs receiving midazolam at increased CSF pressure, although these occurred in fewer frequency bins and at fewer time intervals following flumazenil than when flumazenil was administered at normal CSF pressure.

In the present study certain findings support the suitability of the methodology and experimental design for the purposes of this study. Control values for $V_f$ were similar to previously reported control values for dogs not receiving midazolam\textsuperscript{13,14} and dogs receiving midazolam.\textsuperscript{12} Values for $V_f$ did not change when CSF pressure was increased by 10 cmH$_2$O, consistent with previous reports that small increases in CSF pressure do not alter $V_f$.\textsuperscript{16} Values for $V_f$ also did not change when CSF pressure was

---

**Table 3. Aperiodic Analysis of EEG Activity Prior to Administration of Flumazenil (mean ± SD)**

<table>
<thead>
<tr>
<th></th>
<th>Dogs Receiving Midazolam (n = 6)</th>
<th>Dogs Not Receiving Midazolam (n = 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normal CSF Pressure</td>
<td>Increased CSF Pressure</td>
</tr>
<tr>
<td>$\delta$ Power ($\mu V^2 \cdot 10^{-9} \cdot \text{min}^{-1}$)</td>
<td>41.3 ± 17.3</td>
<td>62.2 ± 39.6</td>
</tr>
<tr>
<td>Power (waves/minute)</td>
<td>53 ± 3</td>
<td>64 ± 50</td>
</tr>
<tr>
<td>$\theta$ Power ($\mu V^2 \cdot 10^{-9} \cdot \text{min}^{-1}$)</td>
<td>63.7 ± 33.7*</td>
<td>84.4 ± 48.4*</td>
</tr>
<tr>
<td>Waves (number/minute)</td>
<td>125 ± 50*</td>
<td>120 ± 50*</td>
</tr>
<tr>
<td>$\alpha$ Power ($\mu V^2 \cdot 10^{-9} \cdot \text{min}^{-1}$)</td>
<td>97.8 ± 53.8*</td>
<td>70.5 ± 42.8*</td>
</tr>
<tr>
<td>Waves (number/minute)</td>
<td>177 ± 59*</td>
<td>167 ± 68*</td>
</tr>
<tr>
<td>$\beta$ Power ($\mu V^2 \cdot 10^{-9} \cdot \text{min}^{-1}$)</td>
<td>89.2 ± 39.3</td>
<td>74.6 ± 41.5</td>
</tr>
<tr>
<td>Waves (number/minute)</td>
<td>462 ± 185†</td>
<td>448 ± 196†</td>
</tr>
<tr>
<td>Total power ($\mu V^2 \cdot 10^{-9} \cdot \text{min}^{-1}$)</td>
<td>285.6 ± 136.7</td>
<td>294.6 ± 149.2</td>
</tr>
<tr>
<td>Activity edge (Hz)</td>
<td>14 ± 3</td>
<td>13 ± 5</td>
</tr>
</tbody>
</table>

* The combination of $\theta$ and $\alpha$ power and number of waves was significantly different from dogs not receiving midazolam by multiple ANOVA, $P < 0.05$.

† Significantly different from dogs not receiving midazolam as determined by one-way ANOVA, $P < 0.05$. 
increased to 46–48 cmH₂O, consistent with previous reports that V₀ does not decrease as long as cerebral perfusion pressure remains greater than ∼70 mmHg.¹⁷,¹⁸ Control values for ⁸ were similar to previously reported control values at normal CSF pressure both in dogs not receiving midazolam¹³,¹⁴ and in dogs receiving midazolam.¹² ⁸ decreased when CSF pressure was increased to 36–38 cmH₂O, consistent with previous reports that ⁸ is relatively stable at CSF pressure < 25–30 cmH₂O and decreases at CSF pressures > 25–30 cmH₂O.³,¹⁹,²⁰ The EEG of dogs receiving midazolam was comprised of less high frequency activity than in dogs not receiving midazolam, as previously reported.¹² Increase of CSF pressure to 36–38 cmH₂O produced no significant change in EEG power, number of waves, or the activity edge, in accordance with reports that EEG activity does not change significantly as long as cerebral perfusion pressure remains >50–40 mmHg.²¹ Values in dogs examined first at increased CSF pressure and then at normal CSF pressure were not different from values examined first at normal CSF pressure and then at increased CSF pressure, indicating that the magnitude of increase and technique for increase of CSF pressure in this study did not produce irreversible changes in CSF dynamics, the EEG, or systemic values. When CSF pressure was increased to approximately 21, 37, and 47 cmH₂O, the increase of CSF pressure equaled the distance in centimeters by which the distal end of the cisternal outflow tubing was raised, indicating that the integrity of the perfusion system was intact.

The results of the present study indicate that flumazenil exerts little direct action on V₀, R₈, or EEG activity in the absence of a preexisting benzodiazepine effect. In dogs receiving midazolam, both doses of flumazenil produced inconsistent increases in R₈ and the larger dose reversed the increase of α and θ EEG activity seen with midazolam. The potential clinical relevance of the present findings relates to the effects of flumazenil on both CSF pressure and accommodation by CSF volume to changes in intracranial volume when flumazenil is used to reverse ben-
TABLE 4. Systemic Values* and CSF Osmolality (mean ± SD)

<table>
<thead>
<tr>
<th></th>
<th>Dogs Receiving Midazolam (n = 6)</th>
<th>Dogs Not Receiving Midazolam (n = 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normal CSF Pressure</td>
<td>Increased CSF Pressure</td>
</tr>
<tr>
<td>CSF osmolality (mOsm/kg)</td>
<td>318 ± 8</td>
<td>—</td>
</tr>
<tr>
<td>P&lt;sub&gt;CO&lt;/sub&gt; (mmHg)</td>
<td>38 ± 2</td>
<td>38 ± 4</td>
</tr>
<tr>
<td>pH</td>
<td>7.32 ± 0.02</td>
<td>7.32 ± 0.02</td>
</tr>
<tr>
<td>Bicarbonate (mEq/l)</td>
<td>19.0 ± 1.0</td>
<td>18.8 ± 1.4</td>
</tr>
<tr>
<td>P&lt;sub&gt;02&lt;/sub&gt; (mmHg)</td>
<td>137 ± 11</td>
<td>136 ± 8</td>
</tr>
<tr>
<td>Hemoglobin (g/dl)</td>
<td>14.6 ± 1.6</td>
<td>14.5 ± 1.5</td>
</tr>
<tr>
<td>Heart rate (beats/min)</td>
<td>111 ± 17</td>
<td>109 ± 14</td>
</tr>
<tr>
<td>Temperature, nasopharyngeal (°C)</td>
<td>37.2 ± 0.4</td>
<td>37.2 ± 0.4</td>
</tr>
</tbody>
</table>

* Values did not differ between experimental conditions and were therefore combined.

zodiazepine effects. Both CSF pressure and contraction of CSF volume are regulated by V<sub>T</sub> and R<sub>a</sub>. Because flumazenil produces no change in V<sub>T</sub> and inconsistent increases in R<sub>a</sub>, CSF pressure will rise when increased R<sub>a</sub> causes V<sub>T</sub> to decrease relative to V<sub>F</sub>. In addition, when R<sub>a</sub> is increased, the magnitude of contraction of CSF volume (in response to increase of cerebral blood volume or brain tissue volume) decreases, thereby augmenting the effect of increase of cerebral blood volume or brain tissue volume on CSF pressure. Because the increase in R<sub>a</sub> produced by flumazenil is inconsistent and relatively small, it is not likely to be clinically important.

References
1. Fleischer JE, Mikes JE, Moyer TP, Michenfelder JD: Cerebral
effects of high dose midazolam and subsequent reversal with RO 15-1788 in dogs. Anesthesiology 68:234-242, 1988
2. Gregory TK, Pettus DC: An electroencephalographic processing
algorithm specifically intended for analysis of cerebral electrical
3. Mann JD, Butler AB, Rosenthal JE, Maffeo Cj, Johnson RN, Bass
NH: Regulation of intracranial pressure in rat, dog, and man.
4. Smith NT, Westover Cj Jr, Quinn M, Benthuyzen JL, Silver HD,
Sanford TJ Jr: An electroencephalographic comparison of
alfentanil with other narcotics and with thiopental. J Clin Monit
1:236-244, 1985
5. Davson H: Chemical composition and secretory nature of the fluids,
Physiology of the Cerebrospinal Fluid. Edited by Davson H.
6. Artru AA: Effects of enflurane and isoflurane on resistance to
reabsorption of cerebrospinal fluid in dogs. Anesthesiology
61:529-533, 1984
7. Artru AA, Hornbein TF: Closed ventriculocisternal perfusion
to determine CSF production rate and pressure. Am J Physiol
251: R996-R999, 1986
8. Heseey SR, Held D, pumpkinmeier JR: Bulk flow and diffusion in
the cerebrospinal fluid system of the goat. Am J Physiol
203: 775-781, 1962
9. Pumpkinmeier JR, Heseey SR, Jordan EF, Downer J: Perfusion of
the cerebral ventricular system in unanesthetized goats. Am J
Physiol 203:763-774, 1962
10. Artru AA, Hornbein TF: Prolonged hypocapnia does not alter
the rate of CSF production in dogs during halothane anesthesia
or sedation with nitrous oxide. Anesthesiology 67:66-71, 1987
Handbook of Statistics. Edited by Brunning JL, Kintz GL.
Glenview, Scott, Foresman, 1977, pp 18-106
12. Artru AA: Dose-related changes in the rate of cerebrospinal fluid
formation and resistance to reabsorption of cerebrospinal fluid
following administration of thiopental, midazolam and etomidate
in dogs. Anesthesiology 69:541-546, 1988
13. Artru AA: Reduction of cerebrospinal fluid pressure by hypopcapnia:
Changes in cerebral blood volume, cerebrospinal fluid volume,
and brain tissue water and electrolytes. J Cereb Blood
Flow Metab 7:471-479, 1987
14. Artru AA: Muscle relaxation with succinylcholine or vecuronium
does not alter the rate of CSF production or resistance to reabsorption
of CSF in dogs. Anesthesiology 68:392-396, 1988
15. Steel RGD, Torrie JH: Analysis of variance. I. The one-way
classification, Principles and Procedures of Statistics. Edited by Steel
16. Wood JH: Physiology, pharmacology, and dynamics of cerebrospinal
fluid, Neurobiology of Cerebrospinal Fluid, Vol. 1. Edited by
17. Weiss MH, Wertman N: Modulation of CSF production by alterations
18. Carey ME, Vela AR: Effect of systemic arterial hypotension on
the rate of CSF formation in dogs. J Neurosurg 41:550-555, 1974
19. Johnson RN, Maffeo Cj, Butler AB, Mann JD, Bass NH: Intracranial
hypertension in experimental animals and man: Quantitative
approach to system dynamics of circulatory cerebrospinal fluid,
Neurobiology of Cerebrospinal Fluid, Vol. 2. Edited by
20. Mann JD, Butler AB, Johnson RN, Bass NH: Clearance of macromolecular
and particulate substances from the cerebrospinal fluid system of the rat. J Neurosurg
50:343-348, 1979